These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 21734183)

  • 1. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.
    Mazzone E; Vasco G; Sormani MP; Torrente Y; Berardinelli A; Messina S; D'Amico A; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Gasperini S; Previtali S; Napolitano S; Martinelli D; Bruno C; Vita G; Comi G; Bertini E; Mercuri E
    Neurology; 2011 Jul; 77(3):250-6. PubMed ID: 21734183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy.
    Mazzone ES; Pane M; Sormani MP; Scalise R; Berardinelli A; Messina S; Torrente Y; D'Amico A; Doglio L; Viggiano E; D'Ambrosio P; Cavallaro F; Frosini S; Bello L; Bonfiglio S; De Sanctis R; Rolle E; Bianco F; Magri F; Rossi F; Vasco G; Vita G; Motta MC; Donati MA; Sacchini M; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Napolitano S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E
    PLoS One; 2013; 8(1):e52512. PubMed ID: 23326337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures.
    Lerario A; Bonfiglio S; Sormani M; Tettamanti A; Marktel S; Napolitano S; Previtali S; Scarlato M; Natali-Sora M; Mercuri E; Bresolin N; Mongini T; Comi G; Gatti R; Ciceri F; Cossu G; Torrente Y
    BMC Neurol; 2012 Sep; 12():91. PubMed ID: 22974002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F;
    Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy.
    Silva EC; Machado DL; Resende MB; Silva RF; Zanoteli E; Reed UC
    Arq Neuropsiquiatr; 2012 Mar; 70(3):191-5. PubMed ID: 22392111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.
    Pane M; Mazzone ES; Sivo S; Sormani MP; Messina S; D'Amico A; Carlesi A; Vita G; Fanelli L; Berardinelli A; Torrente Y; Lanzillotta V; Viggiano E; D Ambrosio P; Cavallaro F; Frosini S; Barp A; Bonfiglio S; Scalise R; De Sanctis R; Rolle E; Graziano A; Magri F; Palermo C; Rossi F; Donati MA; Sacchini M; Arnoldi MT; Baranello G; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E
    PLoS One; 2014; 9(10):e108205. PubMed ID: 25271887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers.
    Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS
    Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.
    Rabbia M; Guridi Ormazabal M; Staunton H; Veenstra K; Eggenspieler D; Annoussamy M; Servais L; Strijbos P
    J Neuromuscul Dis; 2024; 11(3):701-714. PubMed ID: 38640165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years.
    Evans WJ; Hellerstein M; Butterfield RJ; Smith E; Guglieri M; Katz N; Nave B; Branigan L; Thera S; Vordos KL; Behar L; Schiava M; James MK; Field T; Mohammed H; Shankaran M
    J Physiol; 2024 Oct; 602(19):4929-4939. PubMed ID: 39216089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.